دورية أكاديمية

Talazoparib (Tala) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

التفاصيل البيبلوغرافية
العنوان: Talazoparib (Tala) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
المؤلفون: Srkalovic, Gordan, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Ahn, Eugene R, Brouse, Gregory, Chan, John K, Mehmi, Inderjit, Khalil, Maya, Duvivier, Herbert Leon, Gaba, Anu G., Leuva, Harshraj, Thota, Ramya, Yost, Kathleen J, Grantham, Gina N., Gregory, Abigail, Hinshaw, Dominique C., Halabi, Susan, Schilsky, Richard L.
المصدر: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p3115-3115, 1p
قاعدة البيانات: Supplemental Index
الوصف
تدمد:0732183X
DOI:10.1200/JCO.2023.41.16_suppl.3115